Microcap Ledger CNS Pharmaceuticals, Inc. $CNSP
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Houston, TX
- Fiscal year end
- December 31
- Shares outstanding
- 1,461,449 [10-Q 2026-08-12]
What the company doesAI summary of filing
CNS Pharmaceuticals is a biotechnology company that develops drug candidates for neurology and oncology indications. As of early 2026, the company is executing a strategic shift from its historical focus on glioblastoma to building a broader pipeline in neurology and oncology through the identification and in-licensing of clinical-stage and preclinical assets. The company is currently pre-revenue and is exploring out-licensing opportunities for its legacy programs, TPI 287 and Berubicin, which were designed to treat brain cancers. CNS Pharmaceuticals generates no product revenues and is dependent on capital financing to support its development activities. [10-K 2026-03-31]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$7.53M | −$8.19M | $19.98M | [10-Q 2026-08-12] |
| FY ended Dec 2025 | — | −$16.0K | −$13.81M | $7.20M | [DEF 14A 2026-08-21] |
| FY ended Dec 2024 | — | −$14.9K | −$17.11M | $6.46M | [DEF 14A 2026-08-21] |
- Quarterly cash burn
- −$4.09M
- Cash runway Estimate
- ~14.6 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2025-03-31 | 2,944,381 | [10-K/A 2025-04-30] |
| 2025-05-15 | 5,461,951 | [10-Q 2025-05-15] |
| 2025-08-14 | 574,580 | [10-Q 2025-08-14] |
| 2025-11-14 | 620,290 | [10-Q 2025-11-14] |
| 2026-03-31 | 811,449 | [10-K 2026-03-31] |
| 2026-04-27 | 811,449 | [10-K/A 2026-04-30] |
| 2026-05-13 | 1,461,449 | [10-Q 2026-05-14] |
| 2026-08-11 | 1,461,449 | [10-Q 2026-08-12] |
- Shelf registration
- S-3 filed 2026-05-19; declared effective 2026-05-26 [S-3 2026-05-19]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-08-14 | Levin Rami | exercise | 4,750 | — | [4 2026-08-18] |
| 2026-05-18 | Fisher Michal | buy | 2,000 | $5.00 | [4 2026-08-18] |
| 2026-05-18 | Charles Faith L. | buy | 7,100 | $4.79 | [4 2026-05-20] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-02 | 8-K | Director or officer change; Shareholder vote results |
| 2026-08-21 | DEF 14A | Proxy statement |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-12 | 10-Q | Quarterly report |
| 2026-07-02 | 8-K | Regulation FD disclosure |
| 2026-05-26 | 424B3 | Prospectus or prospectus supplement |
| 2026-05-19 | S-3 | Registration statement |
| 2026-05-15 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-14 | 10-Q | Quarterly report |
| 2026-05-04 | 8-K | Material agreement entered; Unregistered sale of equity; Director or officer change |
| 2026-04-30 | 10-K/A | Amended report |
| 2026-04-17 | 13G | Beneficial ownership report (5%+ holder) |
Alerts for $CNSP
Email me when CNS Pharmaceuticals, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.